Targeted therapy in metastatic renal cell carcinoma efficacy, adverse-event management and key considerations

Gespeichert in:
Bibliographische Detailangaben
Format: Buch
Sprache:English
Veröffentlicht: Amsterdam [u.a.] Elsevier 2007
Schriftenreihe:EJC Supplements ; 5,7
Schlagworte:
Online-Zugang:Inhaltsverzeichnis
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

MARC

LEADER 00000nam a2200000 cb4500
001 BV023008905
003 DE-604
005 20080327
007 t|
008 071119s2007 xx a||| |||| 00||| eng d
035 |a (OCoLC)254137394 
035 |a (DE-599)BVBBV023008905 
040 |a DE-604  |b ger  |e rakwb 
041 0 |a eng 
049 |a DE-355  |a DE-19  |a DE-20 
245 1 0 |a Targeted therapy in metastatic renal cell carcinoma  |b efficacy, adverse-event management and key considerations 
264 1 |a Amsterdam [u.a.]  |b Elsevier  |c 2007 
300 |a 34 S.  |b Ill. 
336 |b txt  |2 rdacontent 
337 |b n  |2 rdamedia 
338 |b nc  |2 rdacarrier 
490 1 |a EJC : Supplements  |v 5,7 
650 0 7 |a Metastase  |0 (DE-588)4125915-4  |2 gnd  |9 rswk-swf 
650 0 7 |a Hypernephrom  |0 (DE-588)4161076-3  |2 gnd  |9 rswk-swf 
650 0 7 |a Targeted drug delivery  |0 (DE-588)4302415-4  |2 gnd  |9 rswk-swf 
655 7 |0 (DE-588)4143413-4  |a Aufsatzsammlung  |2 gnd-content 
689 0 0 |a Hypernephrom  |0 (DE-588)4161076-3  |D s 
689 0 1 |a Metastase  |0 (DE-588)4125915-4  |D s 
689 0 2 |a Targeted drug delivery  |0 (DE-588)4302415-4  |D s 
689 0 |5 DE-604 
830 0 |a EJC  |v Supplements ; 5,7  |w (DE-604)BV017615175  |9 5,7 
856 4 2 |m HBZ Datenaustausch  |q application/pdf  |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016213148&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA  |3 Inhaltsverzeichnis 
943 1 |a oai:aleph.bib-bvb.de:BVB01-016213148 

Datensatz im Suchindex

DE-19_call_number 0760/4 Med.GZ 262s(5,5/9
DE-19_location 55
DE-BY-UBM_katkey 3790568
DE-BY-UBM_media_number 99994638990
_version_ 1823053863312162816
adam_text IT5 EJC SUPPLEMENTS 2007 Contents Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse event management and key considerations Targeted therapy in metastatic renal cell carcinoma: efficacy, adverse event management and key considerations A. Rauaud 1 Current options for the treatment of locally advanced and metastatic renal cell carcinoma: focus on sunitinib A. Rauaud 4 Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse event management S. Negrier, A. Rauaud 12 Key considerations in patient selection for the use of targeted therapy in metastatic renal cell carcinoma A. Rauaud 20 Case Report 1. Sunitinib malate in patients with pre existing haematological abnormalities A. Bamias 28 Case Report 2. Severe erythema multiforme induced by two consecutive anti angiogenic drugs M.S. Dilhuydy, T. Jouary, A. Gomez, H. Walkrand, G. Pastkier, A. Rauaud 30 Case Report 3. Sunitinib malate in patients with cerebellar metastases S. Negrier 32 *gM»g gftgfc Indexed/Abstracted in: 3||||I|||||| Current Contents; jSgBSrar^ EMBASE/Excerpta Medica; icnuMco/in y*PNtP $i , , w j ,,cnnUr ISSN 1359 6349 ^^a Index Medicus; MEDLINE; ft 4fn»C CABS, BIOS/S Database; ELSEVIER PASCAL CNRS Database; CINAHLs®
any_adam_object 1
building Verbundindex
bvnumber BV023008905
ctrlnum (OCoLC)254137394
(DE-599)BVBBV023008905
format Book
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01470nam a2200361 cb4500</leader><controlfield tag="001">BV023008905</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20080327 </controlfield><controlfield tag="007">t|</controlfield><controlfield tag="008">071119s2007 xx a||| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)254137394</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV023008905</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield><subfield code="a">DE-19</subfield><subfield code="a">DE-20</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Targeted therapy in metastatic renal cell carcinoma</subfield><subfield code="b">efficacy, adverse-event management and key considerations</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Amsterdam [u.a.]</subfield><subfield code="b">Elsevier</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">34 S.</subfield><subfield code="b">Ill.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">EJC : Supplements</subfield><subfield code="v">5,7</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Metastase</subfield><subfield code="0">(DE-588)4125915-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hypernephrom</subfield><subfield code="0">(DE-588)4161076-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Targeted drug delivery</subfield><subfield code="0">(DE-588)4302415-4</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4143413-4</subfield><subfield code="a">Aufsatzsammlung</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Hypernephrom</subfield><subfield code="0">(DE-588)4161076-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Metastase</subfield><subfield code="0">(DE-588)4125915-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Targeted drug delivery</subfield><subfield code="0">(DE-588)4302415-4</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">EJC</subfield><subfield code="v">Supplements ; 5,7</subfield><subfield code="w">(DE-604)BV017615175</subfield><subfield code="9">5,7</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&amp;doc_library=BVB01&amp;local_base=BVB01&amp;doc_number=016213148&amp;sequence=000002&amp;line_number=0001&amp;func_code=DB_RECORDS&amp;service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="943" ind1="1" ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-016213148</subfield></datafield></record></collection>
genre (DE-588)4143413-4 Aufsatzsammlung gnd-content
genre_facet Aufsatzsammlung
id DE-604.BV023008905
illustrated Illustrated
indexdate 2025-02-03T17:14:18Z
institution BVB
language English
oai_aleph_id oai:aleph.bib-bvb.de:BVB01-016213148
oclc_num 254137394
open_access_boolean
owner DE-355
DE-BY-UBR
DE-19
DE-BY-UBM
DE-20
owner_facet DE-355
DE-BY-UBR
DE-19
DE-BY-UBM
DE-20
physical 34 S. Ill.
publishDate 2007
publishDateSearch 2007
publishDateSort 2007
publisher Elsevier
record_format marc
series EJC
series2 EJC : Supplements
spellingShingle Targeted therapy in metastatic renal cell carcinoma efficacy, adverse-event management and key considerations
EJC
Metastase (DE-588)4125915-4 gnd
Hypernephrom (DE-588)4161076-3 gnd
Targeted drug delivery (DE-588)4302415-4 gnd
subject_GND (DE-588)4125915-4
(DE-588)4161076-3
(DE-588)4302415-4
(DE-588)4143413-4
title Targeted therapy in metastatic renal cell carcinoma efficacy, adverse-event management and key considerations
title_auth Targeted therapy in metastatic renal cell carcinoma efficacy, adverse-event management and key considerations
title_exact_search Targeted therapy in metastatic renal cell carcinoma efficacy, adverse-event management and key considerations
title_full Targeted therapy in metastatic renal cell carcinoma efficacy, adverse-event management and key considerations
title_fullStr Targeted therapy in metastatic renal cell carcinoma efficacy, adverse-event management and key considerations
title_full_unstemmed Targeted therapy in metastatic renal cell carcinoma efficacy, adverse-event management and key considerations
title_short Targeted therapy in metastatic renal cell carcinoma
title_sort targeted therapy in metastatic renal cell carcinoma efficacy adverse event management and key considerations
title_sub efficacy, adverse-event management and key considerations
topic Metastase (DE-588)4125915-4 gnd
Hypernephrom (DE-588)4161076-3 gnd
Targeted drug delivery (DE-588)4302415-4 gnd
topic_facet Metastase
Hypernephrom
Targeted drug delivery
Aufsatzsammlung
url http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=016213148&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA
volume_link (DE-604)BV017615175